Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 24, Number 7—July 2018
Research

Pneumococcal Meningitis in Adults after Introduction of PCV7 and PCV13, Israel, July 2009–June 20151

Gili Regev-YochayComments to Author , Klaris Reisenberg, Michal Katzir, Yonit Wiener-Well, Galia Rahav, Jacob Strahilevitz, Valery Istomin, Evgenia Tsyba, Avi Peretz, Shirley Khakshoor, Ron Dagan, on behalf of the Israeli Adult Invasive Pneumococcal Disease Group
Author affiliations: Sheba Medical Center, Ramat Gan, Israel (G. Regev-Yochay, G. Rahav, S. Khakshoor); Tel Aviv University, Tel Aviv, Israel (G. Regev-Yochay, M. Katzir, G. Rahav); Soroka Medical Center, Beersheba, Israel (K. Reisenberg); Bar-Ilan University, Safed, Israel (K. Reisenberg, A. Peretz); Meir Medical Center, Kfar Saba, Israel (M. Katzir); Shaare Zedek Medical Center, Jerusalem, Israel (Y. Wiener-Well); Hadassah-Hebrew University, Jerusalem (J. Strahilevitz); Hillel Yaffe Medical Center, Hadera, Israel (V. Istomin); Barzilai Medical Center, Ashkelon, Israel (E. Tsyba); Baruch Padeh Medical Center, Tiberias, Israel (A. Peretz); Ben-Gurion University of the Negev, Beersheba (R. Dagan)

Main Article

Table 4

Multivariate logistic model for predictors of meningitis among patients not at risk for IPD, Israel, July 1, 2009–June 30, 2015*

Variable Adjusted OR (95% CI) Adjusted p value
Age, y
18–49 Referent
50–64 2.13 (1.16–3.91) 0.015
>65
 1.90 (1.02–3.55)
 0.042
Concurrent medical conditions
None Referent
Any† 0.48 (0.27–0.85) 0.011
No history of previous trauma Referent
Previous trauma 9.78 (2.24–42.75) 0.002
No lipid disorder Referent
Lipid disorder 2.73 (1.19–6.24) 0.017
No history of Infections Referent
Recurrent or chronic infections‡ 12.31 (3.86–39.22) <0.0001
No history of dementia Referent
Dementia
 0.12 (0.02–0.91)
 0.040
Serotype
Non-23 Referent
23 5.43 (2.01–14.70) 0.0009

*Patients not at risk for IPD were defined as those without any recognized concurrent medical condition for which PPSV23 administration is recommended. IPD, invasive pneumococcal disease; OR, odds ratio; PPSV23, pneumococcal polysaccharide vaccine 23.
†Any concurrent medical condition, excluding those for which PPSV23 is recommended. Patients with these conditions were not included in the not at-risk group.
‡Various types of recurrent or chronic infections, including chronic otitis media, sinusitis, recurrent cellulitis, chronic osteomyelitis, and tuberculosis.

Main Article

1Some results from this study were presented at the 10th International Symposium on Pneumococci and Pneumococcal Diseases, June 26–30, 2016, Glasgow, Scotland.

2Additional members of the Israeli Adult Invasive Pneumococcal Disease Group are listed at the end of this article.

Page created: June 18, 2018
Page updated: June 18, 2018
Page reviewed: June 18, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external